Director · Intellia Therapeutics, Inc. · Common Stock
Grant or award — administrative, little informational value
No reported dollar value · 37.8% of prior position
Disclosed 1 business day after execution (deadline: 2)
First recorded trade by this actor in this security
No clustered activity in the dataset
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 20 | ARK Investment Management LLC13F filer |  NTLAIntellia Therapeutics, Inc.ADD | BUY | $40.04M 2.37M sh | Aug 14, 2026 | |
| 27 | Dube Michael PVP, Chief Accounting Officer | NTLAIntellia Therapeutics, Inc. Open-market sale | SELL | $44K 2,641 sh | Jul 6, 2026 traded Jul 1, 2026 | |
| 9 | Goodman JesseDirector | NTLAIntellia Therapeutics, Inc. Grant or award | A | — 13.3K sh | Jun 10, 2026 traded Jun 9, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Goodman Jesse filed this Form 4 reporting a grant or award of NTLA on Jun 9, 2026. It became public on Jun 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.